MX9202781A - Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana. - Google Patents

Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana.

Info

Publication number
MX9202781A
MX9202781A MX9202781A MX9202781A MX9202781A MX 9202781 A MX9202781 A MX 9202781A MX 9202781 A MX9202781 A MX 9202781A MX 9202781 A MX9202781 A MX 9202781A MX 9202781 A MX9202781 A MX 9202781A
Authority
MX
Mexico
Prior art keywords
vaccine
treatment method
human immunodeficiency
immunodeficiency viruses
viruses
Prior art date
Application number
MX9202781A
Other languages
English (en)
Inventor
Gale E Smith
Volvovitz Franklin
Original Assignee
Microgenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys Inc filed Critical Microgenesys Inc
Publication of MX9202781A publication Critical patent/MX9202781A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX9202781A 1991-06-11 1992-06-10 Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana. MX9202781A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11

Publications (1)

Publication Number Publication Date
MX9202781A true MX9202781A (es) 1993-04-01

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202781A MX9202781A (es) 1991-06-11 1992-06-10 Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana.

Country Status (18)

Country Link
EP (1) EP0542998A1 (es)
JP (1) JPH06501851A (es)
CN (1) CN1068266A (es)
AU (2) AU2193192A (es)
BG (1) BG97519A (es)
CA (1) CA2087732A1 (es)
EE (1) EE9400183A (es)
FI (1) FI930577A (es)
HU (1) HUT68355A (es)
IE (1) IE921875A1 (es)
IL (1) IL102092A (es)
LT (1) LT3365B (es)
MX (1) MX9202781A (es)
PL (1) PL297849A1 (es)
PT (1) PT100584A (es)
SK (1) SK18993A3 (es)
WO (1) WO1992022654A1 (es)
ZA (1) ZA924150B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
WO1995017515A1 (en) 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
AU723537B2 (en) 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
ES2416629T3 (es) * 2002-12-03 2013-08-02 University Of Massachusetts Vacunas polivalentes de ADN de glicoproteína de VIH-1 primaria y procedimientos de vacunación
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
US9122778B2 (en) 2009-05-27 2015-09-01 Biotempus Limited Methods of treating diseases
US20140234337A1 (en) 2011-08-19 2014-08-21 Immortal Spirit Limited Antibody and antibody-containing composition
CN102961760B (zh) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 重叠肽作为制备皮肤试验和检测特异性细胞免疫的试剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Also Published As

Publication number Publication date
LTIP335A (en) 1995-01-31
EE9400183A (et) 1995-12-15
AU4028895A (en) 1996-02-22
EP0542998A1 (en) 1993-05-26
AU2193192A (en) 1993-01-12
FI930577A (fi) 1993-03-24
SK18993A3 (en) 1993-10-06
HU9300686D0 (en) 1993-06-28
PT100584A (pt) 1993-07-30
WO1992022654A1 (en) 1992-12-23
FI930577A0 (fi) 1993-02-10
CA2087732A1 (en) 1992-12-12
HUT68355A (en) 1995-06-28
IE921875A1 (en) 1992-12-16
ZA924150B (en) 1993-02-24
BG97519A (bg) 1994-03-24
IL102092A (en) 1996-11-14
PL297849A1 (en) 1994-01-24
LT3365B (en) 1995-07-25
IL102092A0 (en) 1993-01-14
JPH06501851A (ja) 1994-03-03
CN1068266A (zh) 1993-01-27

Similar Documents

Publication Publication Date Title
MX9202781A (es) Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana.
MX9202564A (es) Vidrio de fluoroaluminosilicato y metodo para tratarlo.
CY2007030I1 (el) Εμβολιο εναντια στον ανθρωπινο ϊο θηλωματος (τυπος 18)
BR9606769A (pt) Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete
NO985200L (no) Antimikrobiell behandling for herpes simplex virus, og andre infeksi÷se syk
BG97198A (bg) Диалкокси-пиридинил-бензимидазолови производни, метод за получаването им и тяхното фармацевтично приложение
SI0831921T1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
NO922275D0 (no) Aryletere, deres fremstilling og fremgangsmaate for behandling
EP0676954A4 (en) HIV LOCK VIRUS.
BG97200A (bg) Заместени бензимидазоли,метод за получаването им и тяхното фармацевтично приложение
HU9201746D0 (en) Recombinant avipox virus, the virus infected cell cultivation and the vaccine resulted from it for poultry vaccination
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
ITMI913092A0 (it) Vaccino di poxvirus ricombinate del virus del morbillo
NO971495D0 (no) Svekkede virus og fremgangsmåte til deres fremstilling
EP0292293A3 (en) Newcastle disease virus vaccine and method for the applicaton thereof
FR2715304B1 (fr) Vaccin anti-allergique.
MX9202912A (es) Nuevos anticuerpos monoclonales dirigidos contra el virus de la inmunosuficiencia humana y proceso para su preparacion.
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
BR9205290A (pt) Vacine e metodo de tratamento de infeccao do virus de imunodeficiencia humana
DE69106733D1 (de) Fleischbehandlung.
EP0624372A3 (en) Medication for the treatment of HIV infections.
EP0678033A4 (en) VACCINE AGAINST AIDS DERIVED FROM THE REVERTING LIVESTOCK VIRUS.
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
DE58902466D1 (de) Acyl-carnitin zur behandlung und zur verhuetung von virusinfektionen.
ZA883365B (en) Newcastle disease virus vaccine and method for the application thereof